Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

周三，Cantor Fitzgerald分析师Kristen Kluska将Supernus Pharmaceuticals（NASDAQ:SUPN）的评级从"增持"下调至"中性"。同时将目标价从此前的57.00美元大幅下调至36.00美元。根据 InvestingPro 数据显示，SUPN展现出强劲的财务状况，毛利率高达89%，且现金储备超过债务，维持稳健的资产负债表。

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

Cantor Fitzgerald last night downgraded Supernus (SUPN) to Neutral from Overweight with a price target of $36, down from $57. The firm cites ...

Shares of Supernus Pharmaceuticals stock opened at $34.59 on Wednesday. The company has a market cap of $1.91 billion, a PE ratio of 32.33 and a beta of 0.90. The business has a 50 day moving ...

The phase IIb study results of Supernus Pharmaceuticals Inc.’s SPN-820 in treatment-resistant depression had pulled the company’s stock (NASDAQ:SUPN) down 15.6% on Feb. 19. The randomized, ...